Optical coherence tomography (OCTA) observed signs of moving suspended scattering particles (SSPiM) in RVO-ME and their clinical significance

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058266

Enrollment

Unknown

Registered

2022-04-04

Start date

2022-04-01

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion (RVO)

Interventions

SSPiM group:Anti-VEGF therapy

Non-SSPiM group:Anti-VEGF therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. RVO-ME patients diagnosed by FFA; 2. Cooperate with OCTA and fundus photographic examination; 3. OCTA images are clear and readable, RTVue OCT signal index >=50; 4. (NCT) Intraocular pressure < 22mmHg.

Exclusion criteria

Exclusion criteria: 1. Significant macular anterior membrane, active retinal or optic disc neovascularization, active or old choroid neovascularization, iris neovascularization, active eye infection, anaprystalline or anterior chamber iols, obvious refractive media opacity, and previous history of corticosteroid IOP; 2. The affected eye has received anticoagulant drugs or any anti-VEGF or steroid treatment; 3. Have received intraocular surgery or laser treatment; 4. Glaucoma, ocular tumors, diabetic retinopathy, systemic and ocular immunity, infectious diseases, pregnancy, etc.

Design outcomes

Primary

Measure	Time frame
Gene polymorphisms;Proteomics;Metabolomics;	—

Countries

China

Contacts

Public ContactWang Liwen

Dalian NO.3 People's Hospital

106820691@qq.com+86 13704111125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026